KOD Jan 2025 3.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:33PM EDT. Market open.
Loading interactive chart…
- Zacks
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
- Zacks
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences:
© 2024 Yahoo. All rights reserved.